Evidence map›Paper›PMID 35005430›Full record

ArticleAntibody therapeutics2022

Structural arrangement of the VH and VL domains in the COBRA™ T-cell engaging single-chain diabody.

Jessica Krakow, Michal Hammel, Ying Zhu, Brian J Hillier, Bryce Paolella, Austin Desmarais, Rusty Wall, Tseng-Hui T Chen, Rex Pei, Chulani Karunatilake and 2 more

Open access · goldAbstract read
In one paragraph

Article in Antibody therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 75% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Jessica KrakowMaverick Therapeutics, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Brisbane, CA, USA.
Michal HammelMolecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
Ying ZhuMaverick Therapeutics, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Brisbane, CA, USA.
Brian J HillierMaverick Therapeutics, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Brisbane, CA, USA.
Bryce PaolellaMaverick Therapeutics, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Brisbane, CA, USA.
Austin DesmaraisMaverick Therapeutics, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Brisbane, CA, USA.
Rusty WallMaverick Therapeutics, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Brisbane, CA, USA.
Tseng-Hui T ChenMaverick Therapeutics, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Brisbane, CA, USA.ORCID https://orcid.org/0000-0003-0419-4335
Rex PeiMaverick Therapeutics, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Brisbane, CA, USA.
Chulani KarunatilakeMaverick Therapeutics, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Brisbane, CA, USA.
Robert DuBridgeMaverick Therapeutics, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Brisbane, CA, USA.
Maia VinogradovaMaverick Therapeutics, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Brisbane, CA, USA.
Takeda (United States) · USLawrence Berkeley National Laboratory · US

Funding

User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI PAUL David ADAMS, Gregory L Hura · 2017 to 2026
$28.6M
NIGMS NIH HHS P30 GM124169
6 · The paper itself

Abstract

backgroundCOBRA™ (COnditional Bispecific Redirected Activation) T-cell engagers are designed to target solid tumors as a single polypeptide chain prodrug that becomes activated by proteolysis in the tumor microenvironment. One COBRA molecule comprises seven Ig domains: three single-domain antibodies (sdAbs) recognizing a tumor target or human serum albumin (HSA), and CD3ε-binding variable fragment heavy chain (VH) and variable fragment light chain (VL) and their inactivated counterparts, VHi and VLi. Pairing of VH and VL, and VLi and VHi into single-chain variable fragments (Fv) is prevented by shortened inter-domain linkers. Instead, VH and VL are expected to interact with VLi and VHi, respectively, thus making a diabody whose binding to CD3ε on the T-cells is impaired.

methodsWe analyzed the structure of an epidermal growth factor receptor (EGFR) COBRA in solution using negative stain electron microscopy (EM) and small-angle X-ray scattering (SAXS).

resultsWe found that this EGFR COBRA forms stable monomers with a very dynamic interdomain arrangement. At most, only five domains at a time appeared ordered, and only one VH-VL pair was found in the Fv orientation. Nonenzymatic posttranslational modifications suggest that the CDR3 loops in the VL-VHi pair are exposed but are buried in the VH-VLi pair. The MMP9 cleavage rate of the prodrug when bound to recombinant EGFR or HSA is not affected, indicating positioning of the MMP9-cleavable linker away from the EGFR and HSA binding sites.

conclusionHere, we propose a model for EGFR COBRA where VH and VLi form an Fv, and VL and VHi do not, possibly interacting with other Ig domains. SAXS and MMP9 cleavage analyses suggest that all COBRA molecules tested have a similar structural architecture.

Indexed as

antibodydiabodyprotein therapeuticSAXSstructureT-cell engager

Identifiers

PMID35005430
PMCPMC8719580
OpenAlexW4200194634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.